TOP TEN perturbations for 39650_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39650_s_at
Selected probe(set): 229202_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39650_s_at (229202_at) across 6674 perturbations tested by GENEVESTIGATOR:
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary)
Relative Expression (log2-ratio):-3.3904657Number of Samples:2 / 3
Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type of the soft tissue (subcutaneously implanted). | |
Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, malignant peripheral nerve sheath tumor of the soft tissue (subcutaneously implanted). |
precursor-B-ALL study 3 (MLL-rearranged) / T-ALL study 3
Relative Expression (log2-ratio):-3.3683796Number of Samples:5 / 29
Experimental | precursor-B-ALL study 3 (MLL-rearranged) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
Control | T-ALL study 3 |
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
T-cell activation study 2 / quiescent CD4+ T-cell sample
Relative Expression (log2-ratio):-3.1634321Number of Samples:2 / 2
Experimental | T-cell activation study 2 |
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 2 days.. | |
Control | quiescent CD4+ T-cell sample |
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors. |
T-cell activation study 1 / quiescent CD4+ T-cell sample
Relative Expression (log2-ratio):-3.1516638Number of Samples:2 / 2
Experimental | T-cell activation study 1 |
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day. | |
Control | quiescent CD4+ T-cell sample |
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors. |
lung cancer study 1 (PDX; basaloid carcinoma; primary) / lung cancer study 1 (PDX; adenosquamous carcinoma; primary)
Relative Expression (log2-ratio):3.1408653Number of Samples:3 / 4
Experimental | lung cancer study 1 (PDX; basaloid carcinoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted). | |
Control | lung cancer study 1 (PDX; adenosquamous carcinoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenosquamous carcinoma of the lung (subcutaneously implanted). |
medulloblastoma study 2 / non-tumor brain tissue
Relative Expression (log2-ratio):-3.1157293Number of Samples:4 / 9
Experimental | medulloblastoma study 2 |
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma. | |
Control | non-tumor brain tissue |
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor. |
CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Relative Expression (log2-ratio):3.0664377Number of Samples:3 / 3
Experimental | CAR T cell study 4 (PSCA-28t28Z; post-infusion) |
CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples). | |
Control | CAR T cell study 4 (PSCA-28t28Z; pre-infusion) |
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary)
Relative Expression (log2-ratio):3.0306635Number of Samples:6 / 2
Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted). | |
Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type of the soft tissue (subcutaneously implanted). |
HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Relative Expression (log2-ratio):-2.8135462Number of Samples:3 / 3
Experimental | HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) |
Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C. | |
Control | HIF-1a/HIF-2a depletion study 1 (normoxia; AB81) |
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. |
lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)
Relative Expression (log2-ratio):-2.7999716Number of Samples:2 / 3
Experimental | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). | |
Control | lung cancer study 1 (PDX; basaloid carcinoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted). |